tradingkey.logo

Dyadic International Inc

DYAI
1.000USD
+0.090+9.89%
收盘 12/19, 16:00美东报价延迟15分钟
36.18M总市值
亏损市盈率 TTM

Dyadic International Inc

1.000
+0.090+9.89%

关于 Dyadic International Inc 公司

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Dyadic International Inc简介

公司代码DYAI
公司名称Dyadic International Inc
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)
员工数量6
证券类型Ordinary Share
年结日Nov 05
公司地址1044 North U.S. Highway One
城市JUPITER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33477
电话15617438333
网址https://dyadic.com/
公司代码DYAI
上市日期Nov 05, 2004
CEOEmalfarb (Mark A)

Dyadic International Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Apis Capital Advisors LLC
4.26%
Chapin Davis Asset Management
2.58%
The Vanguard Group, Inc.
2.53%
其他
68.14%
持股股东
持股股东
占比
Emalfarb (Mark A)
13.07%
Francisco Trust
9.42%
Apis Capital Advisors LLC
4.26%
Chapin Davis Asset Management
2.58%
The Vanguard Group, Inc.
2.53%
其他
68.14%
股东类型
持股股东
占比
Individual Investor
15.84%
Corporation
9.42%
Investment Advisor
9.03%
Hedge Fund
5.29%
Investment Advisor/Hedge Fund
1.74%
Bank and Trust
0.93%
Venture Capital
0.07%
Research Firm
0.06%
其他
57.62%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
67
6.19M
14.14%
--
2025Q3
69
6.19M
14.21%
+1.17M
2025Q2
67
5.02M
17.34%
-34.61K
2025Q1
64
5.06M
17.41%
-179.68K
2024Q4
66
5.12M
16.50%
+343.55K
2024Q3
64
4.78M
17.00%
+94.58K
2024Q2
63
4.69M
16.54%
+162.98K
2024Q1
59
4.53M
16.61%
-322.18K
2023Q4
60
4.51M
16.85%
+7.33K
2023Q3
68
4.51M
17.97%
-1.09K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Emalfarb (Mark A)
4.73M
13.07%
--
--
Apr 24, 2025
Francisco Trust
3.41M
9.42%
--
--
Apr 24, 2025
Chapin Davis Asset Management
882.85K
2.44%
+40.00K
+4.75%
Jun 30, 2025
The Vanguard Group, Inc.
860.66K
2.38%
+46.32K
+5.69%
Jun 30, 2025
Truist Bank
250.00K
0.69%
--
--
Jun 30, 2025
Tarnok (Michael P)
281.03K
0.78%
+10.78K
+3.99%
Jun 20, 2025
Geode Capital Management, L.L.C.
259.15K
0.72%
+732.00
+0.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
249.82K
0.69%
+2.96K
+1.20%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Dyadic International Inc的前五大股东是谁?

Dyadic International Inc 的前五大股东如下:
Emalfarb (Mark A)持有股份:4.73M,占总股份比例:13.07%。
Francisco Trust持有股份:3.41M,占总股份比例:9.42%。
Chapin Davis Asset Management持有股份:882.85K,占总股份比例:2.44%。
The Vanguard Group, Inc.持有股份:860.66K,占总股份比例:2.38%。
Truist Bank持有股份:250.00K,占总股份比例:0.69%。

Dyadic International Inc的前三大股东类型是什么?

Dyadic International Inc 的前三大股东类型分别是:
Emalfarb (Mark A)
Francisco Trust
Apis Capital Advisors LLC

有多少机构持有Dyadic International Inc(DYAI)的股份?

截至2025Q4,共有67家机构持有Dyadic International Inc的股份,合计持有的股份价值约为6.19M,占公司总股份的14.14%。与2025Q3相比,机构持股有所增加,增幅为-0.07%。

哪个业务部门对Dyadic International Inc的收入贡献最大?

在--,--业务部门对Dyadic International Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI